Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Ophthalmology

Genentech’s Faricimab Meets Primary Endpoint in 2 Global Phase III Studies, Shows Potential to Extend Treatment Frequency

Genentech announced positive topline results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational bispecific […]

Genentech’s Faricimab Meets Primary Endpoint in 2 Global Phase III Studies, Shows Potential to Extend Treatment Frequency
1 month ago
Share

Ocuphire Pharma Announces ORION-1 Phase 2 Results for Nyxol Published in Clinical Ophthalmology

Ocuphire Pharmaceuticals announced that results from its ORION-1 Phase 2 clinical trial evaluating the safety and efficacy of Nyxol in glaucoma […]

Ocuphire Pharma Announces ORION-1 Phase 2 Results for Nyxol Published in Clinical Ophthalmology
1 month ago
Share

Bausch + Lomb Announces Phase 2 Dry Eye Study Data Published in Cornea: The Journal of Cornea and External Disease

Bausch + Lomb announced that the results from the Phase 2 SEECASE clinical study, evaluating NOV03 (perfluorohexyloctane) ophthalmic solution in […]

Bausch + Lomb Announces Phase 2 Dry Eye Study Data Published in Cornea The Journal of Cornea and External Disease
2 months ago
Share

Bringing the Clinical Research as a Care Option to the Ophthalmology Practice: An Intriguing Path

In a recent special piece for Ophthalmology Times Dr. Jason R. Chin with Andover Eye (Andover, MA) and Dr. Gary […]

Bringing the Clinical Research as a Care Option to the Ophthalmology Practice An Intriguing Path
3 months ago
Share

Duke Disease Retinal Imaging (DNRI) Repository Initiative Big Implications for Diagnosing & Treating Neurodegenerative Disease

Researchers are developing a powerful, new kind of patient registry by using optical coherence tomography, angiography, and ultra-widefield fundus photography. […]

Duke Disease Retinal Imaging (DNRI) Repository Initiative Big Implications for Diagnosing & Treating Neurodegenerative Disease
6 months ago
Share

jCyte Reports Positive Results from Phase 2b Trial of jCell in Retinitis Pigmentosa

Enthera Pharmaceuticals announced the completion of a €28 million Series A financing round co-led by seed investor Sofinnova Partners and […]

jCyte Reports Positive Results from Phase 2b Trial of jCell in Retinitis Pigmentosa
7 months ago
Share

Kaiser Permanente Participates Pathbreaking Study to Better Understand Genetics of Near Sightedness

Kaiser Permanente investigators are looking into the underlying genetic factors behind near-sightedness or myopia. The team has closed in on […]

Kaiser Permanente Participates Pathbreaking Study to Better Understand Genetics of Near Sightedness
11 months ago
Share

AGTC Reports Positive Interim 6-Month Data from Dose Escalation Cohorts of Ongoing Phase 1/2 Trials in Achromatopsia

Applied Genetics Technologies Corp. announced positive interim six-month data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical trials, […]

AGTC Reports Positive Interim 6-Month Data from Dose Escalation Cohorts of Ongoing Phase 12 Trials in Achromatopsia
1 year ago
Share

Horizon Therapeutics Announces FDA Approval of Tepezza (teprotumumab-trbw) for Thyroid Eye Disease

Horizon Therapeutics announced the U.S. FDA has approved Tepezza (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). Tepezza is […]

Horizon Therapeutics Announces FDA Approval of Tepezza (teprotumumab-trbw) for Thyroid Eye Disease
1 year ago
Share

Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial for Dry Eye Disease

Oyster Point Pharma announced positive results from their phase 2 Mystic trial, which evaluated OC-01 nasal spray as compared to […]

Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial for Dry Eye Disease
1 year ago
Share

Posts navigation

Older posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.